Xembify
Bacterial Infections
Grifols Therapeutics LLCPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Bacterial Infections cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NORMAL HUMAN SERUM ALBUMIN EASL - CLIF Consortium | Phase 4 | BB |
L-Ofloxacin Children's Oncology Group | Phase 3 | BB |
Mucoid Exopolysaccharide P. Aeruginosa Immune Globulin Iv National Center for Research Resources (NCRR) | Phase 2 | B |
Clindamycin Phillip Brian Smith | Phase 1 | CC |
Same molecule, other indications
Xembify is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →